Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

PROVENT
  NCT04625725		 RCTcilgavimab and tixagevimab (Evusheld)placeboCOVID-19 prophylaxis (excluding children)low
3460/1737 conclusif
  • demonstrated 77 % decrease in symptomatic Covid-19 (PE) with a high degree of certainty due to low risk of bias
  • suggested 96 % decrease in hospitalization with a high degree of certainty due to low risk of bias
reduced risk of developing symptomatic COVID-19 by 77% (95% confidence interval (CI): 46, 90), compared to placebo.
BLAZE-2 US (Cohen)
  NCT04497987		 RCTbamlanivimab monotherapyplaceboCOVID-19 prophylaxis (excluding children)some concern
588/587 conclusif
  • demonstrated 57 % decrease in infection (PCR positive symptomatic or not) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • statistically significant 1.0-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
1 study excluded by filtering options (0 RCT / 1 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons